Oncolytic Adenoviral Mutants with E1B19K Gene Deletions Enhance Gemcitabine-induced Apoptosis in Pancreatic Carcinoma Cells and Anti-Tumor Efficacy In vivo

Stephan Leitner,1 Katrina Sweeney,1 Daniel Öberg,1 Derek Davies,2 Enrique Miranda,1 Nick R. Lemoine,1 and Gunnel Halldénn1

Abstract

Purpose: Pancreatic adenocarcinoma is a rapidly progressive malignancy that is highly resistant to current chemotherapeutic modalities and almost uniformly fatal. We show that a novel targeting strategy combining oncolytic adenoviral mutants with the standard cytotoxic treatment, gemcitabine, can markedly improve the anticancer potency.

Experimental Design: Adenoviral mutants with the E1B19K gene deleted with and without E3B gene expression (AdΔE1B19K and dl337 mutants, respectively) were assessed for synergistic interactions in combination with gemcitabine. Cell viability, mechanism of cell death, and antitumor efficacy in vivo were determined in the pancreatic carcinoma cells PT45 and Suit2, normal human bronchial epithelial cells, and in PT45 xenografts.

Results: The ΔE1B19K-deleted mutants synergized with gemcitabine to selectively kill cultured pancreatic cancer cells and xenografts in vivo with no effect in normal cells. The corresponding wild-type virus (Ad5) stimulated drug-induced cell killing to a lesser degree. Gemcitabine blocked replication of all viruses despite the enhanced cell killing activity due to gemcitabine-induced delay in G1/S-cell cycle progression, with repression of cyclin E and cdc25A, which was not abrogated by viral E1A-expression. Synergistic cell death occurred through enhancement of gemcitabine-induced apoptosis in the presence of both AdΔE1B19K and dl337 mutants, shown by increased cell membrane fragmentation, caspase-3 activation, and mitochondrial dysfunction.

Conclusions: Our data suggest that oncolytic mutants lacking the antiapoptotic E1B19K gene can improve efficacy of DNA-damaging drugs such as gemcitabine through convergence on cellular apoptosis pathways. These findings imply that less toxic doses than currently practiced in the clinic could efficiently target pancreatic adenocarcinomas when combined with adenoviral mutants.
Translational Relevance

Pancreatic adenocarcinoma is an aggressive malignancy, highly resistant to current chemotherapeutic modalities, which is among the leading causes of cancer-related deaths globally because it presents late at an advanced stage. The current standard of care is gemcitabine but although this produces extension of survival it is rarely curative. Here we show that oncolytic mutants with deletion of the anti-apoptotic E1B19K gene can significantly improve the antitumor efficacy of gemcitabine through the enhancement of cell death through apoptosis.

These findings are important for the future design of combination therapies and particularly the potential of oncolytic mutants to target gemcitabine-insensitive cancers.

pRb-pathway alterations (10, 11) and tissue-specific promoter-driven mutants targeting prostate cancer (12, 13) or the majority of solid tumors (14, 15). Pancreatic adenocarcinoma shows prevalent genetic alterations in the pRb, cell cycle, and cell death pathways, making it a suitable target for the more recently developed potent pRb-functional mutants (dld922-947, ref. 10; Ad5A24, ref. 11) with potential for highly improved clinical outcomes. In preclinical models, cell killing was reported superior to the dl1520 mutant, whereas tumor selectivity was less specific with replication in cycling normal cells. Consequently, further modifications are necessary to improve on tumor selectivity as well as efficacy in combination with cytotoxic therapies.

The viral anti-apoptotic gene E1B19K has been suggested as a potential candidate gene for deletion in already potent replication-selective complementation mutants to minimize toxicity in normal cells (16–18). E1B19K, a functional Bcl-2 homologue, directly binds Bax and Bak-inhibiting oligomerization and mitochondrial pore-formation to block apoptosis (19, 20). The biological function of E1B19K is to inhibit death receptor–induced signaling by preventing Bax-Bak association and enable viral replication and spread. E1B19K also inhibits intrinsically induced apoptosis (both p53-dependent and p53-independent), for example in response to viral E1A proteins or cytotoxic drugs (17, 18, 21–23). In contrast, E1B55K mainly functions independently, for example in response to viral E1A proteins or intrinsically induced apoptosis (both p53-dependent and p53-independent), which enables viral replication and spread. E1B55K also inhibits mitochondrial pore-formation to block apoptosis of normal cells (16–18). E1B19K, a functional Bcl-2 homologue, directly binds Bax and Bak-inhibiting oligomerization and mitochondrial pore-formation to block apoptosis (19, 20). The biological function of E1B19K is to inhibit death receptor–induced signaling by preventing Bax-Bak association and enable viral replication and spread. E1B19K also inhibits intrinsically induced apoptosis (both p53-dependent and p53-independent), for example in response to viral E1A proteins or cytotoxic drugs (17, 18, 21–23). In contrast, E1B55K mainly functions independently, for example in response to viral E1A proteins or intrinsically induced apoptosis (both p53-dependent and p53-independent), which enables viral replication and spread.

We here report on the efficacy and selectivity of novel mutants with and without E1B19K and E3B expression in combination with gemcitabine targeting pancreatic cancers. Treatment with gemcitabine, a cytotoxic nucleotide analogue (2’,2’-difluoro-2’-deoxycytidine; dFdC), results in block of DNA synthesis through chain termination, activation of the DNA damage response, induction of cell death, and inhibition of cell proliferation (27). Our data show that deletion of the E1B19K gene, both in the presence and absence of an intact E3 region, can potentely sensitize pancreatic carcinoma cells to gemcitabine-induced death. Combinations of suboptimal doses of oncolytic mutants with gemcitabine resulted in greatly improved cell killing and antitumor efficacy in vivo, with minimal toxicity in normal cells. Although the response was E1A-dependent, neither viral replication nor cell cycle progression was required.

Materials and Methods

Cancer cell lines and adenoviruses. Human pancreatic adenocarcinoma cell lines PT45 and Suit-2 (Cell Services, CRUK) and normal human bronchial epithelial cells (NHBE; Clonetics/Cambrex) were cultured in DMEM supplemented with 10% FCS (Life Technologies) or according to the manufacturer’s instructions, respectively. The following viruses and mutants were used: adenovirus type 5 wild-type (Ad5), Ad5E1B19K (E1B19K-deleted Ad5), dl309 (E3B-deleted), dl337 (E1B19K- and E3-deleted), dl312 (E1A- and E3B-deleted), and AdGFP (cytomegalovirus–green fluorescent protein cassette replacing E1-region). Mutants were constructed using the pAdEas system (Stratagene) or by recombination of the complete Ad5 genome (28).

All viruses used in the study had a viral particle to infectious unit ratio (vp/pfu) of 10–40.

Cell killing assay and synergistic interactions. Cells were infected with viruses and/or treated with gemcitabine (Gemzar; Eli Lilly) 24 h after seeding, assayed 3 or 6 d later using the MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxysphenyl)-2(4-sulphophenyl)-2H-tetrazolium] assay (Promega) to quantify live cells as an indirect measure of cell death. Dose response curves were generated to calculate the concentration of each agent killing 50% of cells (EC50) using untreated cells or cells treated with one agent only as controls, as previously described (29). Ten-fold dilutions were prepared starting at 1 × 105 particles per cell (ppc) for virus and at 400 μmol/L for gemcitabine. Each data point was generated from triplicate samples and repeated three to five times.

Adenovirus replication assay. Cells were infected with viral mutants at 100 ppc and treated with gemcitabine at 5 nmol/L, 10 nmol/L, or 10 μmol/L, and both simultaneous and sequential additions 24 h apart were evaluated. Cells and media were collected, freeze-thawed, and titered on H293 cells by limiting dilution method (TCID50; ref. 26). Each assay was repeated two to three times, averaged, and expressed as pfu/cell ± SD. An internal control of known activity was included in each assay.

Quantitative PCR. Cells were infected with viral mutants at 100 ppc and/or treated with gemcitabine at 5 μmol/L, 10 μmol/L, or 10 μmol/L for 3, 24, 48 and 72 h followed by RNA extraction (RNeasy Kit; Qiagen). First-strand cDNA was synthesized from 1 μg total RNA using MMLV-Reverse Transcriptase (RT) and random hexamer primers (Taqman; Applied Biosystems). Expression levels of E1A-, penton-, and cellular 18S-mRNAs were determined using the following primers: E1A-forward; 5’- TGCCAAAAATTTGTACCCGA-3’, E1A-reverse; 5’- CGTCCTCTAAGGGTGATGTTGAA-3’, penton-forward; 5’-GATCGGAAACCTCCTTGAGAAA-3’, penton-reverse; 5’- CGTACGGCGGGCGCGTTTG-3’, 18S-RNA forward; 5’- CGCCGCTGAGGATT-3’, and reverse; 5’- CATTCTGCGAACATTGTTGCG-3’. Standard curves were generated using pCR4-TOPO-vectors containing E1A or penton and for...
For quantification of viral genome amplification, DNA was isolated from cells treated as described above, and E1A-DNA and hexon-DNA were detected by SYBR Green, with hexon-forward: 5'-TGCTGTCACCTGCGGTCTTG-3' and reverse: 5'-GGACAGGCC-pcDNA3'-3'. For penton cDNA to cellular 18S cDNA (g/g), was analyzed by the System SDS software, and expressed as the ratio of E1A was done with the Power SYBR Green Master Mix (Applied Biosystems), analyzed by the System SDS software, and expressed as the ratio of E1A or penton cDNA to cellular 18S cDNA (g/g) was separated on SDS-polyacrylamide gels under reducing conditions, transferred to polyvinylidene fluoride membranes (Millipore), and detected by the following antisera: rabbit anti-Ad2 E1A at 1:200 (SC-430; Santa Cruz Biotechnology), rabbit antihexon at 1:2000 (AutogenBio), goat antiactin at 1:1000 (SC-1615), rabbit anti-p53 at 1:500 (SC-6243), rabbit anti-cylin D1 at 1:500 (SC-718), rabbit anti-cyclin E at 1:500 (SC-481), rabbit anti-Gdc25A at 1:2000 (Abcam), mouse anti-p21 waf1 at 1:500 (Calbiochem), mouse anti-caspase-3 at 1:500 (Alexis). Detection was by horseradish peroxidase–conjugated secondary IgG-antibodies (Dako) as appropriate, and chemiluminescence reagent (Amersham/Pharmacia) followed by autoradiography (BioMax film; Kodak).

Immunoblot analysis. Subconfluent cells were infected with viruses in the presence of gemcitabine as described above. Cells were harvested at 24, 48, and 72 h postinfection, lysed in buffer (50 mmol/L Hepes, pH 7.4, 250 mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L DTT, 1 mmol/L NaF, 1% Triton X-100) containing protease inhibitors. Total protein (10-20 µg) was separated on SDS-polyacrylamide gels under reducing conditions, transferred to polyvinylidene fluoride membranes (Millipore), and detected by the following antisera: rabbit anti-cyclin E at 1:500 (SC-481), rabbit anti-Cdc25A at 1:2000 (Abcam), rabbit anti-actin at 1:1000 (SC-1615), rabbit anti-hexon at 1:2000 (Alexis), mouse anti-cyclin E at 1:500 (Calbiochem), and goat anti-actin at 1:200 (SC-430; Santa Cruz Biotechnology). Detection was by horseradish peroxidase–conjugated secondary IgG-antibodies (Dako) as appropriate, and chemiluminescence reagent (Amersham/Pharmacia) followed by autoradiography (BioMax film; Kodak).

Fig. 1. Low doses of gemcitabine sensitize pancreatic cancer but not normal cells to E1B19K-deleted mutants. A, viruses used in the study with the respective deletions indicated. PT45 (B) and Sui2 (C) cells were infected with viruses and treated with 5 nmol/L (black) or 10 nmol/L (grey) gemcitabine. D, normal NHBE cells infected with mutants and treated with 5 nmol/L (black), 10 nmol/L (grey) or 10 µmol/L (white) gemcitabine. Cells were analyzed for viability with the MTS assay 3 d after treatment; EC50 values were calculated and presented as percentages of virus-treated compared with control cells, as described in Materials and Methods. Data are the averages of three to four experiments ± SE; *P < 0.05 and **P < 0.01 for B and C, and D is the average of one representative study in triplicate ± SE with *P < 0.05 compared with virus-treated cells.

18S cDNA the quantitative PCR (QPCR) reference total RNA (human; Stratagene). QPCR (7500 Real Time PCR System; Applied Biosystems) was done with the Power SYBR Green Master Mix (Applied Biosystems), analyzed by the System SDS software, and expressed as the ratio of E1A or penton cDNA to cellular 18S cDNA (g/g) = 2-3). Data are presented from representative studies.

For immunoblot analysis, subconfluent cells were infected with viruses in the presence of gemcitabine as described above. Cells were harvested at 24, 48, and 72 h postinfection, lysed in buffer (50 mmol/L Hepes, pH 7.4, 250 mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L DTT, 1 mmol/L NaF, 1% Triton X-100) containing protease inhibitors. Total protein (10-20 µg) was separated on SDS-polyacrylamide gels under reducing conditions, transferred to polyvinylidene fluoride membranes (Millipore), and detected by the following antisera: rabbit anti-Ad2 E1A at 1:200 (SC-430; Santa Cruz Biotechnology), rabbit antihexon at 1:2000 (AutogenBio), goat antiactin at 1:1000 (SC-1615), rabbit anti-p53 at 1:500 (SC-6243), rabbit anti-cylin D1 at 1:500 (SC-718), rabbit anti-cyclin E at 1:500 (SC-481), rabbit anti-Gdc25A at 1:2000 (Abcam), mouse anti-p21 waf1 at 1:500 (Calbiochem), mouse anti-caspase-3 at 1:500 (Alexis). Detection was by horseradish peroxidase–conjugated secondary IgG-antibodies (Dako) as appropriate, and chemiluminescence reagent (Amersham/Pharmacia) followed by autoradiography (BioMax film; Kodak).

Flow cytometric analysis. For detection of cell death markers, cells were infected with viruses at 100 pcp for 2 h followed by addition of gemcitabine at 10 nmol/L or 10 µmol/L, harvested 24 to 96 h postinfection and analyzed for caspase-3 activation (Caspase-3 antibody Apoptosis Kit; BD Pharmingen) and Annexin V staining (Alexa Fluor 488 conjugate; Molecular Probes/Invitrogen). Flow cytometry was done on a FACS Calibur instrument (Becton Dickinson), acquiring 10,000 events per sample from duplicate wells using propidium iodide (Sigma-Aldrich) to exclude dead cells and analyzed using CellQuest software. Treated cells were analyzed for changes in mitochondrial membrane potential (ΔΨm), by staining with tetramethylrhodamine ethyl ester perchlorate (Molecular Probes/Invitrogen) at 60 ng/mL in PBS containing 4-6-diamidino-2-phenylindole at 1 µg/mL and analyzed on an LSRI (Becton Dickinson). For cell cycle analysis, cells were treated and harvested as above, washed in PBS, fixed in 70% ethanol and analyzed for 3 min, treated with 5 µg RNase A (Sigma), and analyzed on a FACS Calibur instrument after addition of 10 µg propidium iodide.

In vivo tumor growth. Tumors were grown in one flank of C57BL athymic (ICRF nu/nu) mice by s.c. implantation of 5 × 106 PT45 cells. Dose responses to viral mutants or gemcitabine were determined by administration of virus intratumorally at 1 × 106 - 107 vp/injection three times at 48-h intervals and gemcitabine at 1.0 to 10.0 mg/kg i.p. twice on days 2 to 8 after virus injection. Tumor volumes were estimated twice weekly: volume = (length × width2/6). Treatments were initiated when tumors were 100 ± 20 µL with tumor growth and progression followed until tumors reached 1.44 cm2 or until symptomatic tumor ulceration occurred (according to UK Home Office Regulations). Treatment groups were balanced by tumor size at the time of treatment initiation (t-test for tumor volumes, P > 0.8). Survival analysis was expressed as time to progression (tumor volume ≥500 µL) was done according to the method of Kaplan-Meier (log rank test for statistical significance). Tumor growth curves were compared using one-way ANOVA for significance.

Assessment of in vivo gene expression. Following treatments of PT45 xenografts, tumors were harvested 30 to 80 d after the last virus administration and snap-frozen in liquid nitrogen (n = 3 per time point.
and group). Tumors were processed for immunohistochemistry of E1A and hexon expression (26).

**Results**

Viral mutant- and gemcitabine-induced, dose-dependent cell death in pancreatic carcinoma cells in culture. Sensitivity to virus- or gemcitabine-induced death was determined in two human pancreatic cell lines, PT45 and Suit2, comparing two E1B19K-deleted mutants, dl337 and Ad5ΔE1B19K, with the respective nondeleted dl309 and Ad5 (Fig. 1A). Both cell lines were relatively insensitive to virus-induced cell death with EC50 values for Ad5 of 532 ± 108 ppc (PT45) and 140 ± 36 ppc (Suit2), for Ad5ΔE1B19K of 994 ± 180 ppc (PT45) and 393 ± 30 ppc (Suit2), and for dl337 and dl309 of 433 ± 118 ppc and 424 ± 110 ppc, respectively, in PT45, and 196 ± 56 ppc and 90 ± 15 ppc, respectively, in Suit2 cells. The nonreplicating mutants dl312 and AdGFP did not induce cell death at doses up to 1 × 107 ppc. Gemcitabine-induced cell death was poor with EC50 values of 0.51 ± 0.11 and 0.88 ± 0.23 μmol/L for PT45 and Suit2, respectively, and was significantly less for NHBE cells with 50% of cells killed between 10 and 100 μmol/L.

**Low doses of gemcitabine sensitized PT45 and Suit2 cells to the deletion mutants.** To test whether combination treatments could enhance cell death in the relatively resistant cell lines, suboptimal concentrations of gemcitabine were tested at 5 and 10 nmol/L, which kill less than 10% of cells when administered alone. In PT45 cells, both drug concentrations greatly sensitized cells to the ΔE1B19K mutants and significantly less to the nondeleted viruses (Fig. 1B). The same effect was observed in Suit2 cells with greatly and selectively enhanced potency for the ΔE1B19K mutants (Fig. 1C). Similarly, when fixed low doses of 10 or 100 ppc of virus were added, sensitization to gemcitabine with enhanced cell death was observed with both Ad5 and Ad5ΔE1B19K (Supplementary Fig. S1). No enhancement of cell death was detected in response to the combinations in NHBE cells using 5 nmol/L or 10 nmol/L gemcitabine, although a 1,000-fold higher concentration (10 μmol/L) caused significant cell death in combination with both viruses (Fig. 1D).

**Gemcitabine inhibits viral replication of all mutants.** Surprisingly, in PT45 cells viral replication was completely abrogated in the presence of 10 nmol/L gemcitabine (<1 pfu/cell; Fig. 2A). Suit2 cells supported higher levels of replication of the virus when used alone but in the presence of gemcitabine, replication was either completely inhibited (Ad5) or detected at very low levels of <4 pfu/cells for the mutants (Fig. 2B). Despite a clear increase in replication over time without drug, both low and high doses of gemcitabine (10 nmol/L and 10 μmol/L) and addition of drug 24 hours prior to or after viral infection, replication was prevented up to 72 hours after gemcitabine treatment. From 96 hours to 144 hours replication was detectable although still significantly attenuated (Supplementary Fig. S2C). Attenuation was also observed to varying degrees in other cell lines and with other viral mutants exemplified by the ovarian SKOV3 cells (Supplementary Fig. S2B). The inhibition was not due to loss in cell viability; after 72 hours more than 85% of cells were viable with 10 nmol/L gemcitabine. However, cell death could have contributed at the higher dose level (10 μmol/L) resulting in only 65% and 40% viable PT45 and Suit2 cells, respectively, after 72 hours. The normal NHBE cells supported replication of all mutants, but in combination with gemcitabine viral replication was potently attenuated at all tested concentrations (Fig. 2C). To verify these novel observations, PT45 cells were analyzed for amplification of viral DNA copies were determined after treatment with 10 nmol/L (striped) and 10 μmol/L (crossed) gemcitabine or with the Ad5ΔE1B19K virus alone (black). Gene amplification was normalized to input virus (3 h after infection; n = 3).
viral genomes by QPCR (Fig. 2D). In Ad5ΔE1B19K-infected cells, a >7-fold increase in viral DNA was determined 24 hours after infection when compared with internalized virus 3 hours after infection, whereas cells treated with 10 nmol/L gemcitabine did not amplify viral DNA above the uptake level. After 48 hours, a further increase in amplification was observed in cells infected with virus alone whereas in the presence of gemcitabine no significant increase was detected (Fig. 2D). Identical results were observed in the Suit2 cells and in wild-type virus–treated cells (Supplementary Fig. S2A and data not shown).

**Gemcitabine decreases viral gene expression.** Despite attenuation of viral replication in the presence of gemcitabine, E1A-proteins were highly expressed over time with all mutants although at slightly lower levels than with virus alone (Fig. 3A and B). Quantitative analysis of E1A mRNA levels showed a clear attenuation in the presence of 10 nmol/L gemcitabine compared with cells infected with virus alone (Fig. 3C). Consistent with the replication data, hexon expression was suppressed in the presence of gemcitabine at 48 hours with all mutants, but expressed after 72 hours (Fig. 3B). A parallel delay in expression of penton transcripts was observed with low levels at 48 hours and slightly increased after 72 hours (Fig. 3D). These data show that sufficient quantities of E1A were present to enable sensitization to the cytotoxic effects of gemcitabine in the absence of viral replication. Interestingly, expression of E1A was also sustained in the NHBE cells up to 72 hours after gemcitabine addition followed by cell detachment and death (Fig. 3B, lower panel). This was in contrast to cells infected with virus alone that were more rapidly detached as a result of potent viral replication (Fig. 2C).

**Low concentration of gemcitabine delay S-phase progression in PT45 cells.** Cell cycle analysis of PT45 cells treated with 10 nmol/L gemcitabine showed arrest of the G1/S-phase up to 48 hours after initial addition of drug followed by gradual

---

**Fig. 3.** Early and late viral genes are expressed in PT45 cells infected with viral mutants in the presence of gemcitabine. A, immunoblot of cells infected with Ad5, Ad5ΔE1B19K, Ad309, or Ad337 and treated with 10 nmol/L gemcitabine. Cell extracts were prepared 48 h after infection and 20 μg of protein loaded in each lane for detection of E1A expression. B, cells infected with Ad5wt and Ad5ΔE1B19K harvested 24 to 72 h after infection and analyzed for E1A and hexon expression (upper panel). Lower panel, light microscopy of NHBE cells grown on glass slides, infected with AdΔ19K in the presence of 10 nmol/L gemcitabine, stained for E1A expression at 24 to 72 h, magnification 200×. C, quantitative reverse transcription-PCR of E1A and (D) penton mRNA levels in response to gemcitabine 24, 48, and 72 h after treatment. Standard curves were prepared for each gene and results were normalized to 18S RNA in every sample, as described in Materials and Methods. Data are representative of two to three experiments.
escape with increased fractions in G2 and sub-G1 (Fig. 4A and B). With 10 μmol/L gemcitabine, a high proportion of cells were dying already during early (24-48 hours) time points resulting in few attached cells and a higher proportion of cells in the sub-G1 fraction in the remaining cells (Fig. 4B). No virally induced effects on cell cycle progression could be detected under these nonsynchronized conditions (Fig. 4A). When viruses and drug were combined, the sub-G1 population increased after 72 to 96 hours with all mutants, exemplified with the data for Ad5ΔE1B19K (Fig. 4A and B).

**Gemcitabine prevents virus induction of S-phase cyclins.** As expected from the cell cycle data, p21 was elevated in response to 10 nmol/L gemcitabine and remained high in the presence of all mutants (Fig. 4C). Basal cyclin D levels were maintained after virus infection but attenuated after the addition of gemcitabine. All viral mutants induced cyclin E and cdc25A whereas gemcitabine inhibited both virus-induced and basal expression. These results show that viral E1A expression is not sufficient to overcome the gemcitabine-induced arrest in response to DNA damage causing attenuation of replication.

The mutant version of p53 present in PT45 cells was constitutively expressed at high levels with no changes corresponding to the drug-induced increase in p21. Cells treated with 10 μmol/L gemcitabine did not show an increase in p21 levels at 24 to 72 hours as expected from the higher levels of cell death and lack of a clear cell cycle arrest under the test conditions (Figs. 4B, Supplementary Fig. S3). To verify the G1-early S-phase arrest as a cause for the attenuated viral replication aphidocholine, a potent blocker of early S-phase, was combined with the viral mutants (Fig. 4D, right). As expected, viral replication was decreased in the presence of this potent DNA-polymerase inhibitor even at low concentrations (Fig. 4D, left).

**Apoptosis-like cell death is increased in response to combination treatments of ΔE1B19K mutants and gemcitabine.** Excluding viral replication as a cause of the enhancement, the mode of

---

**Fig. 4.** Cell cycle analysis of PT45 cells in the presence of viral mutants and gemcitabine. A, flow cytometric analysis of cells treated with gemcitabine at 10 nmol/L, the Ad5ΔE1B19K mutant alone or in combination. Cells were fixed and stained with propidium iodide 24, 48, 72, and 96 h after treatment. B, histograms illustrating the cell cycle-phase distribution in percentages in response to combination treatments with 10 nmol/L or 10 μmol/L gemcitabine and the ΔE1B19K mutant 96 h after treatment; sub-G1 (black), G1 (grey), S (white), and G2/M (top light grey). C, immunoblot of changes in expression levels of cell cycle related proteins in response to mutants and gemcitabine (10 nmol/L) combinations. Cells were harvested 72 h after treatment. D, cells were serum-starved and treated with aphidocholine (5 μg/mL) for 24 and 48 h followed by viral DNA (hexon) amplification (left panel); right, the corresponding cell cycle diagram 24 h after addition of aphidocholine. Gene amplification was normalized to input virus (3 h after infection); data are representative of three studies.
cell death in response to viral gene expression and gemcitabine was explored. We hypothesized that ΔE1B19K mutants could enhance gemcitabine-induced apoptotic death and determined exposure of phosphatidylserine and uptake of propidium iodide. Total apoptotic death (annexin- and propidium iodide–positive) was increased with all viruses in combination with gemcitabine after 48 to 96 hours (Fig. 5A and data not shown). Significant enhancement was observed in cells treated with mutant viruses but not in Ad5-infected cells. The increase in apoptotic death was greatest in combination with the ΔE1B19K mutants, with a >5% increase above what would be expected for simply additive levels. Similarly, activation of caspase-3 showed a clear synergistic enhancement with all viruses in combination with gemcitabine, with the greatest effects in cells infected with the ΔE1B19K mutants (Fig. 5B and Supplementary Fig. S4). Cleavage of procaspase to active caspase-3 was verified by immunoblotting under the same treatment conditions (Fig. 5B, insert). To investigate activation of apoptotic mechanisms upstream of caspase-3, changes in mitochondrial membrane potential (Δψ) were determined by tetramethylrhodamine ethyl ester perchlorate (TMRE) staining and cytometry analysis, expressed as % of live cells with unchanged Δψ (TMRE-positive only). Cells were treated with 10 μmol/L gemcitabine alone or in combination with 100 ppc of each viral mutant. Staurosporin (St)-treated cells (3 μmol/L) were included as a reference for mitochondrial dysfunction (left panel). Right panel, Δψ in response to combinations of mutant or Ad5 with gemcitabine (10 nmol/L) at 96 h in PT45 and SU2 cells. Representative data from four to six studies. Dose response to Ad5ΔE1B19K alone and in combination with 10 nmol/L gemcitabine (G) with and without the pan-caspase inhibitor ZVAD-fmk (Z) at 25 μmol/L. Cell death was determined by MTS assay (left panel). Right, inhibition of cell death by ZVAD-fmk (Z) at 5 and 25 μmol/L in gemcitabine-treated (20 nmol/L) and untreated control cells (Ctrl, 25 μmol/L Z). Data are representative of three experiments with triplicate samples for each study in A, B, and D.

The greatest decrease in membrane potential was in combination with 10 μmol/L gemcitabine and both wild-type and mutant viruses 48 to 96 hours posttreatment (Fig. 5C, left panel). Combinations with the lower dose of 10 nmol/L resulted in a greater loss of potential with the Ad5ΔE1B19K up to 96 hours after treatment (Fig. 5C, right panel, and Supplementary 5S). Addition of the pan-caspase inhibitor ZVAD-fmk completely blocked the enhancement of cell death in response to combination treatment with no significant effect on virus-induced death alone (Fig. 5D, left panel). Gemcitabine-induced cell death was attenuated in a dose-dependent manner (Fig. 5D, right panel). Taken together these results show that both E1B19K-deleted and wild-type viruses potentiate gemcitabine-induced apoptotic cell death through induction of mitochondrial membrane dysfunction following caspase-3 activation. The induction was more potent with both ΔE1B19K mutants. Combination of low doses of gemcitabine and Ad5ΔE1B19K greatly inhibit tumor growth of PT45 xenografts in vivo. The potency of the combination treatments was evaluated in an in vivo PT45 xenograft model with s.c. tumors treated with suboptimal doses of Ad5ΔE1B19K, Ad5, and nonreplicating control virus or with gemcitabine (Fig. 6A and B). In animals treated with the lowest dose of virus at 1 × 10^6 vp, no significant tumor regression or increase in survival was observed.
observed; median survival was 12.5 days for mock versus 35 days for Ad5ΔE1B19K. In combination with 2.5 mg/kg of gemcitabine, time to progression was prolonged to 117 days compared with 35 days and 52 days for each single treatment. In fact, this combination resulted in the same efficacy as the higher dose of virus and was superior to the highest dose of drug. Similar efficacy was determined in combination with Ad5 (Table 1 and data not shown).

In a separate study, Ad5 and Ad5ΔE1B19K were combined with lower doses of gemcitabine at 1 and 2.5 mg/kg, resulting in significant improvements only in combination with the higher dose of drug (Table 1). The corresponding tumor samples stained positive for hexon expression up to 60 days after viral administration both with and without gemcitabine (Fig. 6C). E1A-positive cells could be detected in xenografts treated with the combinations up to 76 days after treatment. E1A-deleted and green fluorescent protein–expressing, E1-deleted, nonreplicating mutants had no efficacy in this model and in combination with gemcitabine did not further inhibit tumor growth nor improve time to progression compared with drug treatment alone (Table 1).

Discussion

Our results show that antitumor efficacy was greatly improved when E1B19K-deleted mutants were combined with subtherapeutic concentrations of the cytotoxic drug gemcitabine. In addition, the sensitization was specific for cancer cells and did not occur in normal cultured cells. Although we and others previously proposed incorporation of the E1B19K deletion in already potent replication-selective oncolytic mutants, this gene deletion had not been studied on its own (16–18, 20, 22, 25). Mutants with additional deletions in death-related genes such as ADP, E1B55K, or E3B were reported to have higher potency and improved spread in cancer cells. During viral infection the E1B55K and E3B genes protect against p53- and death receptor–induced apoptosis, respectively. The Ad5ΔE1B19K mutant used in this study was engineered to lack only the E1B19K antiapoptotic gene and was compared with mutants with E3B deletions with and without E1B19K. Our goal was to establish the role of a single E1B19K deletion in the background of an intact Ad5 backbone prior to construction of combination mutants for oncolytic...
therapy. For the first time, we showed that enhancement of cell death could be achieved with both the single deletion (Ad5ΔE1B19K) and the additional E3B deletion (Ad337) in combination with suboptimal doses of gemcitabine. Although wild-type viruses with intact E1B19K could sensitize cells, the effect was significantly less than with the corresponding mutants. No sensitization was detected in normal cells, which is likely due to the much higher threshold of gemcitabine toxicity (EC50 >10 μmol/L) and perhaps a more efficient antiviral response. These findings suggest that pancreatic adenocarcinomas could be efficiently targeted by less toxic doses than currently practiced in the clinic if combined with oncolytic mutants lacking the antiapoptotic E1B19K gene.

Interestingly, the potent increase in cell death in response to combination treatment was not dependent on viral replication. In fact, replication was prevented in response to all tested concentrations of gemcitabine, a finding not previously reported. Our data showed a nearly complete inhibition up to 72 hours after treatment with detectable levels first at later time points. Other investigators using the modified oncolytic mutant Ad5/3-Δ24 combined with gemcitabine in the ovarian carcinoma cell line SKOV-3 reported a reduction in the initial replication rate whereas total viral yield was unaffected after 96 hours at μmol/L concentrations (30). Although we observed a greater attenuation of replication with Ad5 and Ad5ΔCR2 in SKOV-3 cells combined with 10 mmol/L and 10 μmol/L gemcitabine than reported by Raki et al (30), a similar trend was seen with replication resuming over time paralleling the escape from gemcitabine-induced cell cycle arrest. Gemcitabine-induced attenuation of replication was also reported for replication-selective herpes mutants targeting the pancreatic Capan1, Paca2, and SW1990 human carcinomas (31), whereas in other studies both gemcitabine and fluorouracil were found to stimulate herpes simplex virus replication in pancreatic Hs700T cells (32). Recently, Toth et al. reported that a related cidofovir derivative, CMX001, could potently inhibit adenovirus replication in pancreatic Hs700T cells (32). We found that lower doses of gemcitabine and fluorouracil were found to stimulate herpes simplex virus replication in pancreatic Hs700T cells (32).

In the presence of DNA-damaging drugs such as gemcitabine that induce death through classical apoptosis including DNA damage, mitochondrial depolarization, caspase activation, and nuclear fragmentation, adenoviruses activate cell death through nonapoptotic pathways (37, 38). Although drug-induced caspase-3 activation and loss of mitochondrial potential was enhanced in combination with all viruses, the greatest increase was with the ΔE1B19K mutants. This difference in enhancement was more obvious in the later apoptotic events of membrane fragmentation and exposure of phosphatidylserine where the ΔE1B19K mutants were far more potent than the corresponding wild-type viruses. In agreement with previous studies, no activation of apoptosis was detected with any mutant when given alone although we clearly proved a synergistic increase at several steps in the gemcitabine-induced apoptotic response when combined. A probable cause for the increased apoptotic effects in combination with ΔE1B19K mutants is the proapoptotic function of the E1A products. E1A has been shown to suppress anchorage-independent tumor cell growth, inhibit oncogenes, and directly act on death signaling pathways and to increase cell sensitivity to cytotoxic drugs such as paclitaxel, adriamycin, etoposide, and gemcitabine in carcinoma cells (19, 39–43). In the previous studies an E1A-expressing vector was used and consequently no other viral genes were present to inhibit the apoptotic responses such as the E1B55K, E1B19K, or E3 genes. Similar findings were also reported using replicating viruses with specific gene deletions, suggesting that apoptotic functions of the E1A gene could be blocked by expression of the E1B and E3 genes (44, 45). We speculate that by deleting E1B19K the proapoptotic functions of E1A were not counteracted, further pushing the balance towards apoptosis in the presence of DNA-damaging drugs.

The in vivo studies reported here show the feasibility of combination treatments of oncolytic mutants and DNA-damaging drugs. Both tumor growth inhibition and time to progression were significantly improved when combining doses of virus and gemcitabine that when given alone did not have antitumor efficacy. Despite attenuation of viral replication in cultured cells, we showed potent early and late viral gene expression in vivo up to 30 to 76 days after initial treatment, although whether replication occurred could not be evaluated in these studies. The data show that viral gene expression was sustained for a long period of time in vivo and indicate long-lasting effects on drug sensitization. In our study, gemcitabine and viruses were delivered i.p. and intratumorally, respectively, and most likely drug doses at the tumor site were lower than anticipated perhaps allowing viral replication to proceed. Additional studies would be required to determine the bioavailability, distribution, and half-life of gemcitabine in these models. Both virus and drug were administered at several different time points possibly facilitating viral spread by drug-induced tissue elimination and suppression of the innate immune response preventing virus elimination. To fully
understand the underlying mechanisms of these observations necessitates further investigations. Nevertheless, the clinical implications of possible dose reductions hold promise for improved efficacy and less treatment-associated toxicities in future applications. Interestingly, viral replication was also attenuated in the normal NHBE cells indicating improved safety in the clinical setting. In addition, our previous work suggests that normal cells infected with ΔE1B19K mutants in vivo would be eliminated through tumor necrosis factor-induced apoptosis (16), thus preventing viral spread in normal tissue and further improving the therapeutic index.

Overall our findings show that incorporation of the ΔE1B19K deletion in replication-selective adenoviruses significantly enhanced efficacy of combination therapies with DNA-damaging cytopotoxic chemotherapy. The sensitization to gemcitabine-induced apoptosis was retained even in the presence of intact E1B55K and E3B genes. These findings will aid in the selection of future oncolytic mutants that are likely to incorporate both E1B55K and E3B genes based on previous poor efficacy in vivo when these genes were deleted (5–9, 26). Further studies to investigate whether the enhancement is caused by E1A proapoptotic functions, DNA-damage response, or specific gene alterations and verification in drug- and viral replication-resistant tumor cells will be essential for understanding virus-drug-host interactions.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Acknowledgments
We thank Gary Martin and colleagues at Clare Hall (CRUK) for excellent experimental assistance; Jennelle Francis and Vipul Bhakta (Molecular Oncology Unit) for virus production and QPCR expertise; and Yoshe Wang, Siew Chiat Cheong, and Gioia Cherubini for critical reading of the manuscript and insightful discussions.

References
Oncolytic Adenoviral Mutants with E1B19K Gene Deletions Enhance Gemcitabine-induced Apoptosis in Pancreatic Carcinoma Cells and Anti-Tumor Efficacy In vivo

Stephan Leitner, Katrina Sweeney, Daniel Öberg, et al.


Updated version  Access the most recent version of this article at: http://clincancerres.aacrjournals.org/content/15/5/1730

Supplementary Material Access the most recent supplemental material at: http://clincancerres.aacrjournals.org/content/suppl/2009/02/16/1078-0432.CCR-08-2008.DC1

Cited articles This article cites 45 articles, 14 of which you can access for free at: http://clincancerres.aacrjournals.org/content/15/5/1730.full.html#ref-list-1

Citing articles This article has been cited by 2 HighWire-hosted articles. Access the articles at: http://clincancerres.aacrjournals.org/content/15/5/1730.full.html#related-urls

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.